For the quarter ending 2025-09-30, WVE had -$12,251K decrease in cash & cash equivalents over the period. -$44,914K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -53,852 | -97,347 |
| Amortization of right-of-use assets | 1,374 | 2,620 |
| Depreciation of property and equipment | 856 | 1,740 |
| Share-based compensation expense | 6,472 | 11,149 |
| Accounts receivable | 8,383 | 195 |
| Prepaid expenses | -47 | -2,844 |
| Other assets | -4,847 | 81 |
| Accounts payable | 59 | -1,776 |
| Accrued expenses and other current liabilities | 3,461 | -8,055 |
| Deferred revenue | 2,392 | -16,257 |
| Operating lease liabilities | -1,939 | -3,693 |
| Net cash used in operating activities | -44,666 | -109,051 |
| Purchases of property and equipment | 248 | 471 |
| Net cash used in investing activities | -248 | -471 |
| Proceeds from the issuance of ordinary shares, net of offering costs | 0 | - |
| Proceeds from the issuance of pre-funded warrants, net of offering costs | 0 | - |
| Proceeds from issuance of ordinary shares pursuant to the at-the-market equity program, net of offering costs | 30,212 | 12,361 |
| Proceeds from the exercise of share options | 2,041 | 3,045 |
| Proceeds from the espp | 439 | 442 |
| Net cash provided by financing activities | 32,692 | 15,848 |
| Effect of foreign exchange rates on cash, cash equivalents, and restricted cash | -29 | 101 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -12,251 | -93,573 |
| Cash and cash equivalents at beginning of period | 305,838 | - |
| Cash and cash equivalents at end of period | 200,014 | - |
Wave Life Sciences Ltd. (WVE)
Wave Life Sciences Ltd. (WVE)